News stories about Krystal Biotech (NASDAQ:KRYS) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Krystal Biotech earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.4278598087676 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Separately, Ladenburg Thalmann Financial Services started coverage on Krystal Biotech in a research report on Wednesday, October 18th. They set a “buy” rating and a $23.00 price objective for the company.

Shares of Krystal Biotech (NASDAQ KRYS) traded up $0.20 during trading hours on Tuesday, hitting $9.76. The company had a trading volume of 8,485 shares, compared to its average volume of 27,356. Krystal Biotech has a 1 year low of $9.01 and a 1 year high of $11.98.

In related news, Director Daniel Janney purchased 200,000 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The shares were purchased at an average price of $10.00 per share, with a total value of $2,000,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Suma Krishnan purchased 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The stock was bought at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. Following the purchase, the chief operating officer now directly owns 1,935,249 shares in the company, valued at approximately $19,352,490. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at

Krystal Biotech Company Profile

Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.

Receive News & Stock Ratings for Krystal Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech Inc. and related stocks with our FREE daily email newsletter.